Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
about
Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.Mobile-based patient-provider communication in cancer survivors: The roles of health literacy and patient activation.From the Child's Word to Clinical Intervention: Novel, New, and Innovative Approaches to Symptoms in Pediatric Palliative Care.Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203
P2860
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Feasibility Assessment of Pati ...... center Cancer Clinical Trials.
@en
type
label
Feasibility Assessment of Pati ...... center Cancer Clinical Trials.
@en
prefLabel
Feasibility Assessment of Pati ...... center Cancer Clinical Trials.
@en
P2093
P2860
P1433
P1476
Feasibility Assessment of Pati ...... center Cancer Clinical Trials.
@en
P2093
Alan P Venook
Amylou C Dueck
Andrea M Denicoff
Andrew Himelstein
Ann M O'Mara
Charles Kuzma
David D Biggs
Deborah Schrag
Diana E Lake
Douglas J Weckstein
P2860
P304
P356
10.1001/JAMAONCOL.2016.6749
P50
P577
2017-02-16T00:00:00Z